Aptinyx Inc. (APTX)
(Delayed Data from NSDQ)
$3.78 USD
+0.03 (0.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.79 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.78 USD
+0.03 (0.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.79 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Bicycle (BCYC) up on Collaboration With Novartis for Conjugates
by Zacks Equity Research
Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.
Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug
by Zacks Equity Research
Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up
by Zacks Equity Research
Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
by Zacks Equity Research
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead
by Zacks Equity Research
Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.
Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use
by Zacks Equity Research
The FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. Stock up on Tuesday in response.
Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.
Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up
by Zacks Equity Research
Seagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news.
Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome
by Zacks Equity Research
Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue in the United States.
Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates
by Zacks Equity Research
Regulatory and pipeline updates from Gilead (GILD) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal
by Zacks Equity Research
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy
by Zacks Equity Research
Aptinyx Inc. (APTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Teladoc (TDOC) Plunges 40.3% Since Q1 Earnings Beat: Here's Why
by Zacks Equity Research
Teladoc Health's (TDOC) bet on mental health service BetterHelp is likely to generate lower yield this year.
Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal
by Zacks Equity Research
Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.
Do Options Traders Know Something About Aptinyx (APTX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Aptinyx (APTX) stock based on the movements in the options market lately.
Has Aptinyx Inc. (APTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aptinyx Inc. (APTX) and Doximity (DOCS) have performed compared to their sector so far this year.
Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aptinyx Inc. (APTX) and ICU Medical (ICUI) have performed compared to their sector so far this year.
Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aptinyx Inc. (APTX) and Molina (MOH) have performed compared to their sector so far this year.
Is Acer Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year? (Revised)
by Zacks Equity Research
Here is how Acer Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.
Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aptinyx Inc. (APTX) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
Is Opexa Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Opexa Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.
Are Options Traders Betting on a Big Move in Aptinyx (APTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aptinyx (APTX) stock based on the movements in the options market lately.
Aptinyx Inc. (APTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 16.67% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Aptinyx Inc. (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aptinyx (APTX) Surges on Promising Stress Disorder Study Data
by Zacks Equity Research
Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.